

REMARKS

Claims 1-8, 10-12 and 14-26 are pending. The Office has issued a restriction requirement as follows:

Group I, Claims 1-7, 10-12 and 15-19 drawn to compositions of formula (I)

Group II, Claims 8 and 20-22 drawn to a method of treating with compounds of formula (I)


Group III, Claims 14 and 23-26 drawn to a process for preparing compounds of formula (I).

Applicants elect without traverse the claims of Group I for examination.

The Office also requires an election of species for examination.

Applicants elect the following species without traverse:

:



or (*N*-[3-(4-[[6-((*2R*)-2-[3-(formylamino)-4-hydroxyphenyl]-2-hydroxyethyl)amino)hexyl]oxy)butyl]phenyl]urea).

Currently, Claims 1-8, 10-12, 14-17 and 20-26 read on the elected species. Upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all of the limitations of an allowed generic claim as provided by 37 CFR 1.141.

In addition to the above, Applicants also amend Claims 21-22 such that they depend on Claim 8. Such amendment is not made in view of the prior art.

Substantive examination on the merits is respectfully requested.

Respectfully submitted,

/Robert J. Smith/
Robert J. Smith
Attorney for Applicant
Registration No. 40,820

Date: July 16, 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-9616
Facsimile: 919-483-7977